<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-title>The Journal of Experimental Medicine</journal-title><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10049948</article-id><article-id pub-id-type="pmc">2192948</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Expression of Stromelysin-3 in Atherosclerotic Lesions:  Regulation via CD40&#x02013;CD40 Ligand Signaling In Vitro and In Vivo </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sch&#x000f6;nbeck</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Mach</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Sukhova</surname><given-names>Galina K.</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Atkinson</surname><given-names>Elizabeth</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Levesque</surname><given-names>Ethan</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Herman</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Graber</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Basset</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Libby</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="N0x34a4130N0x3ae6e18">&#x0002a;</xref></contrib></contrib-group><aff id="N0x34a4130N0x3ae6e18">From the <label>&#x0002a;</label>Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of  Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115;  <label>&#x02021;</label>Ares Serono, 1228 Geneva, Switzerland; and the <label>&#x000a7;</label>Institut de G&#x000e9;n&#x000e9;tique et de Biologie Mol&#x000e9;culaire  et Cellulaire, Centre National de la Recherche Scientifique/Institut National de la Sant&#x000e9; et de la  Recherche M&#x000e9;dicale/Universit&#x000e9; Louis Pasteur, BP163, 67404 Illkirch cedex, France</aff><author-notes><fn><p>Address correspondence to Peter Libby, Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood  Ave., LMRC 307, Boston, MA 02115. Phone: 617-732-6628; Fax: 617-732-6961; E-mail: <email>plibby&#x00040;rics.bwh.harvard.edu</email></p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>3</month><year>1999</year></pub-date><volume>189</volume><issue>5</issue><fpage>843</fpage><lpage>853</lpage><history><date date-type="received"><day>22</day><month>10</month><year>1998</year></date><date date-type="rev-recd"><day>21</day><month>12</month><year>1998</year></date></history><copyright-year>1999</copyright-year><abstract><p>Stromelysin-3 is an unusual matrix metalloproteinase, being released in the active rather than  zymogen form and having a distinct substrate specificity, targeting serine proteinase inhibitors  (serpins), which regulate cellular functions involved in atherosclerosis. We report here that human atherosclerotic plaques (<italic>n</italic> &#x0003d; 7) express stromelysin-3 in situ, whereas fatty streaks (<italic>n</italic> &#x0003d; 5)  and normal arterial specimens (<italic>n</italic> &#x0003d; 5) contain little or no stromelysin-3. Stromelysin-3 mRNA  and protein colocalized with endothelial cells, smooth muscle cells, and macrophages within  the lesion. In vitro, usual inducers of matrix metalloproteinases such as interleukin-1, interferon-&#x003b3;, or tumor necrosis factor &#x003b1; did not augment stromelysin-3 in vascular wall cells. However, T cell&#x02013;derived as well as recombinant CD40 ligand (CD40L, CD154), an inflammatory  mediator recently localized in atheroma, induced de novo synthesis of stromelysin-3. In addition, stromelysin-3 mRNA and protein colocalized with CD40L and CD40 within atheroma.  In accordance with the in situ and in vitro data obtained with human material, interruption of  the CD40&#x02013;CD40L signaling pathway in low density lipoprotein receptor&#x02013;deficient hyperlipidemic mice substantially decreased expression of the enzyme within atherosclerotic plaques.  These observations establish the expression of the unusual matrix metalloproteinase stromelysin-3  in human atherosclerotic lesions and implicate CD40&#x02013;CD40L signaling in its regulation, thus  providing a possible new pathway that triggers complications within atherosclerotic lesions.</p></abstract><kwd-group><kwd>atherosclerosis</kwd><kwd>CD40L/CD154</kwd><kwd>matrix metalloproteinase</kwd><kwd>serpins</kwd><kwd>stromelysin-3</kwd></kwd-group></article-meta></front><body><p>The proteinase stromelysin-3 (MMP-11) belongs to the  matrix metalloproteinase (MMP)<sup>1</sup> family, enzymes  which participate in tissue remodeling in a variety of diseases, including tumor metastasis and invasion, arthritis, and  atherogenesis (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>). In contrast to &#x0201c;classical&#x0201d; MMPs, secreted as inactive zymogens, stromelysin-3 is released as an  active enzyme (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). The zymogen contains a unique 10&#x02013; amino acid insert between the pro and catalytic domain  that includes a recognition motif for furin, the Golgi-associated pro protein convertase, which processes stromelysin-3  to its enzymatically active form during traversal through  the constitutive secretory pathway.</p><p>Stromelysin-3 was originally identified by differential  screening of cDNA libraries derived from an invasive breast  cancer surgical specimen and from benign breast fibroadenoma (<xref ref-type="bibr" rid="B11">11</xref>). Stromelysin-3 mRNA and protein expression  correlates with the invasiveness of human carcinomas and  also occurs in some sarcomas or other nonepithelial tumors  (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B15">15</xref>). These, as well as other studies (<xref ref-type="bibr" rid="B16">16</xref>&#x02013;<xref ref-type="bibr" rid="B20">20</xref>), indicated a crucial role for the proteinase in processes characterized by extensive extracellular matrix turnover. Stromelysin-3, however, has a restricted substrate specificity  distinct from all other matrix metalloproteinases. The enzyme only weakly, if at all, degrades extracellular matrix  constituents such as laminin, fibronectin, and collagen (<xref ref-type="bibr" rid="B21">21</xref>,  <xref ref-type="bibr" rid="B22">22</xref>). Instead, substrates of stromelysin-3 include serine proteinase inhibitors, termed serpins (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p><p>The serpin superfamily includes more than 60 proteins,  which can function as inhibitory mediators by acting as suicide substrates for the respective enzyme, with the vast majority targeted towards the serine proteinases known to be  involved in extracellular matrix remodeling, regulation of  blood pressure, modulation of inflammatory responses, cell  migration and differentiation, fibrinolysis, or blood coagulation (<xref ref-type="bibr" rid="B24">24</xref>). This group of serpins consists of single chain  proteins, such as &#x003b1;<sub>1</sub>-proteinase inhibitor (&#x003b1;<sub>1</sub>-PI), &#x003b1;<sub>1</sub>-antitrypsin (&#x003b1;<sub>1</sub>-AT), &#x003b1;<sub>2</sub>-antiplasmin (&#x003b1;<sub>2</sub>-AP), &#x003b1;<sub>2</sub>-macroglobulin  (&#x003b1;<sub>2</sub>-M), plasminogen activator inhibitor, antithrombin III  (AT-III), C1 inhibitor, angiotensinogen, etc. Most of these  serpins have known functions: &#x003b1;<sub>1</sub>-PI acts on elastolytic  proteases, such as leukocyte elastase, and cathepsin G (<xref ref-type="bibr" rid="B25">25</xref>,  <xref ref-type="bibr" rid="B26">26</xref>); &#x003b1;<sub>1</sub>-AT and &#x003b1;<sub>2</sub>-M are involved in lipoprotein catabolism (<xref ref-type="bibr" rid="B27">27</xref>&#x02013;<xref ref-type="bibr" rid="B29">29</xref>); &#x003b1;<sub>1</sub>-AT also inhibits renin and thus the renin&#x02013; angiotensinogen interaction (<xref ref-type="bibr" rid="B30">30</xref>); &#x003b1;<sub>2</sub>-AP and plasminogen  activator inhibitor are involved in the regulation of fibrinolysis; C1 inhibitor is essential for the regulation of activation of the complement and kinin generating system; and  AT-III as well as heparin cofactor II play a central role in  the regulation of blood coagulation (<xref ref-type="bibr" rid="B31">31</xref>). Interestingly, serpins also inhibit matrix degrading enzymes, such as cathepsins (<xref ref-type="bibr" rid="B32">32</xref>). The regulation of matrix degradation may thus  not only be promoted by tissue inhibitors of matrix metalloproteinases/MMP imbalance but also accelerated by decreased  levels of certain serpins such as &#x003b1;<sub>2</sub>-AP or &#x003b1;<sub>1</sub>-PI (<xref ref-type="bibr" rid="B33">33</xref>), inhibitors of matrix degrading activity. In this manner, stromelysin-3, despite possessing weak direct matrix degrading capabilities, might yet play a crucial role in matrix turnover.</p><p>Serpins play critical roles in maintaining homeostasis.  Therefore, any mechanism that reduces the functional level  of members of this superfamily, including inactivation by  proteinases, may result in substantial pathological problems  (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>). Several of the functions listed above relate to atherosclerosis, and atherosclerotic patients exhibit changes in  the levels of several of these serpins, including &#x003b1;<sub>1</sub>-AT, &#x003b1;<sub>2</sub>-M  (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>), and AT-III (<xref ref-type="bibr" rid="B36">36</xref>). In addition, animal studies indicate a potential role of serpins in the inhibition of arterial  intimal thickening (<xref ref-type="bibr" rid="B37">37</xref>) and atherosclerotic plaque development post injury (<xref ref-type="bibr" rid="B38">38</xref>) in vivo. For these reasons, the present  study analyzed the expression of stromelysin-3 within human atherosclerotic lesions.</p><p>Although the expression of stromelysin-3 at sites of  pathologic processes such as Alzheimer's disease or cancer  has prompted great interest in its regulation, little is known  about the mechanisms involved (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). The stromelysin-3 gene promoter differs markedly from previously described matrix metalloproteinase promoters as it lacks a  consensus activator protein 1 binding site and has a functional retinoic acid responsive element. We recently demonstrated the presence of the immune mediators CD40  ligand (CD40L) and its receptor CD40 on endothelial cells  (EC), smooth muscle cells (SMC), and macrophages (M&#x000d8;)  within human atherosclerotic lesions (<xref ref-type="bibr" rid="B41">41</xref>) and showed that  ligation of CD40 induces de novo synthesis of the classical  MMP interstitial collagenase (MMP-1) and the gelatinases  A and B (MMP-2 and -9, respectively) (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>) in these cells.  Therefore, this study also tested the hypothesis that CD40  signaling regulates the expression of the constitutively active matrix metalloproteinase stromelysin-3 in human  atheroma-associated cells and in mouse atheroma in vivo.</p><p>We report here that (a) stromelysin-3 (MMP-11) is  present in human atherosclerotic lesions in situ, (b) cultured human vascular EC, SMC, and M&#x000d8; synthesize  stromelysin-3 de novo upon stimulation with CD40L, and  (c) interruption of CD40&#x02013;CD40L signaling in hyperlipidemic mice diminishes stromelysin-3 expression in atherosclerotic lesions in vivo.</p><sec id="MaterialsMethods" sec-type="materials|methods"><title>Materials and Methods</title><sec disp-level="3"><title>Materials.</title><p>Human recombinant IL-1&#x003b2;, TNF&#x003b1;, and IFN&#x003b3;  were obtained from <named-content content-type="company" xlink:href="endogen">Endogen</named-content>. Phorbol-12 myristate 13-acetate  (PMA) and polymyxin B were purchased from <named-content content-type="company" xlink:href="sigma">Sigma Chemical  Co.</named-content> Human recombinant CD40L (rCD40L) was generated as described previously (<xref ref-type="bibr" rid="B44">44</xref>) and the mouse anti&#x02013;human stromelysin-3  antibody 5ST-4A9 was produced in a program sponsored by  Bristol Myers Squibb and is subject of an issued U.S. utility  patent number 5484726 (<xref ref-type="bibr" rid="B45">45</xref>). Experiments employing rCD40L  were performed in the presence of polymyxin B. Anti-CD40L, a  rat mAb IgG2 antibody raised against mouse CD40L was prepared as described (<xref ref-type="bibr" rid="B46">46</xref>) and provided by <named-content content-type="company" xlink:href="immunex">Immunex Corp.</named-content> Rat IgG  salt-free crystalline powder (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>), reconstituted  in pyrogen-free normal saline and sterile filtered, was obtained  from <named-content content-type="company" xlink:href="immunex">Immunex Corp.</named-content> Both rat anti&#x02013;mouse CD40L antibody and  rat IgG contained &#x0003c;2 pg/&#x003bc;l of endotoxin. Anti&#x02013;human CD40 as  well as control IgG1 mAb (FITC conjugated) used for immunohistochemistry were obtained from <named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>. Low density lipoprotein receptor&#x02013;deficient (LDLR<sup>&#x02212;/&#x02212;</sup>) mice (B6/129LDRr-tm1Her) were obtained from <named-content content-type="company" xlink:href="jackson">Jackson Laboratory</named-content>.</p></sec><sec disp-level="3"><title>Cell Isolation and Culture.</title><p>Human vascular EC were isolated  from saphenous veins by collagenase treatment (1 mg/ml; Worthington Biochemicals) and cultured in dishes coated with fibronectin (1.5 &#x003bc;g/cm<sup>2</sup>; New York Blood Center Reagents).  Cells were maintained in medium 199 (M199; BioWhittaker)  supplemented with 1% penicillin/streptomycin (BioWhittaker),  5% fetal bovine serum (FBS) (Atlanta Biologicals), 50 &#x003bc;g/ml  heparin (<named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>), and endothelial cell growth factor  (Pel-Freez Biological). SMC were isolated from human saphenous veins by explant outgrowth (<xref ref-type="bibr" rid="B47">47</xref>) and cultured in DMEM  (BioWhittaker) supplemented with 1% <sc>l</sc>-glutamine (BioWhittaker), 1% penicillin/streptomycin, and 10% FBS. Both cell types  were subcultured following trypsinization (0.5% trypsin [Worthington Biochemicals]/0.2% EDTA [EM Science]) in 75 cm<sup>2</sup>  culture flasks (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>) and used throughout passages  two to four. Culture media and FBS contained &#x0003c;40 pg endotoxin/ml as determined by chromogenic Limulus amoebocyte assay analysis (QLC-1000; BioWhittaker). EC and SMC were  characterized by immunostaining with anti von Willebrand factor  and anti SMC &#x003b1;-actin antibody (Dako), respectively. Both cell  types were cultured 24 h before the experiment in media lacking  FBS: vascular EC were cultured in M199 supplemented with  0.1% human serum albumin and vascular SMC cultured in insulin/transferrin medium as described previously (<xref ref-type="bibr" rid="B48">48</xref>).</p><p>Mononuclear phagocytes were isolated by density gradient  centrifugation (<xref ref-type="bibr" rid="B49">49</xref>), using lymphocyte separation medium (Organon-Teknika), and subsequent counterflow elutriation from  freshly prepared human PBMCs obtained from leukopacs of  healthy donors (provided by Steve K. Clinton, Dana-Farber Cancer Institute, Boston, MA). Mononuclear phagocytes were used  directly (monocytes) for the experiments or cultured for 1, 3, or  9 d (M&#x000d8;) in RPMI 1640 containing 2% human serum (<named-content content-type="company" xlink:href="sigma">Sigma  Chemical Co.</named-content>). The purity of monocytes/M&#x000d8; was &#x02265;96%, as determined by FACS<sup>&#x000ae;</sup> analysis (anti&#x02013;human CD68 mAb FITC;  <named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>). For certain studies, M&#x000d8; were stimulated in RPMI  1640 lacking serum.</p><p>Freshly isolated human CD4<sup>&#x0002b;</sup> T cells were a gift from Dr. F.W.  Luscinskas (Brigham and Women's Hospital, Boston, MA). The  purity of CD4<sup>&#x0002b;</sup> T cells was &#x02265;98%, as determined by FACS<sup>&#x000ae;</sup>  analysis (anti&#x02013;human CD4 mAb FITC; <named-content content-type="company" xlink:href="calbiochem">Calbiochem</named-content>). Human  CD4<sup>&#x0002b;</sup> T cells were activated with PMA (50 ng/ml, 12 h) and  CD40L cell surface expression confirmed by FACS<sup>&#x000ae;</sup> analysis using FITC-labeled anti&#x02013;human CD40L mAb (<named-content content-type="company" xlink:href="calbiochem">Calbiochem</named-content>). Finally, activated CD4<sup>&#x0002b;</sup> T cell membranes were prepared as described previously (<xref ref-type="bibr" rid="B42">42</xref>) and used for stimulation at a ratio of T  cells to SMC/EC/M&#x000d8; of 10:1.</p></sec><sec disp-level="3"><title>Immunohistochemistry.</title><p>Surgical specimens of human carotid  atheroma and aorta were obtained by protocols approved by the  Human Investigation Review Committee at the Brigham and  Women's Hospital. Serial cryostat sections (5 &#x003bc;m) were cut, air  dried onto microscope slides (<named-content content-type="company" xlink:href="fisher">Fisher Scientific</named-content>), and fixed in acetone at &#x02212;20&#x000b0;C for 5 min. Sections were preincubated with PBS  containing 0.3% hydrogen peroxidase activity. The sections were  then incubated (90 min) with primary or control (mouse myeloma protein MOPC-21; <named-content content-type="company" xlink:href="sigma">Sigma Chemical Co.</named-content>) antibody diluted in PBS supplemented with 5% appropriate serum. After  washing three times in PBS, sections were incubated with the respective biotinylated secondary antibody (45 min; Vector) followed by avidin&#x02013;biotin&#x02013;peroxidase complex (Vectastain ABC  kit; Vector), and antibody binding was visualized with 3-amino-9-ethyl carbazole (Vector) according to the recommendations  provided by the supplier. For colocalization of stromelysin-3  with CD40 or the respective cell type, double immunofluorescence staining was performed. The anti&#x02013;human stromelysin-3  mAb (1:200) was applied for 60 min followed by biotinylated  anti&#x02013;mouse secondary antibody for 45 min and Texas red&#x02013;conjugated streptavidin (<named-content content-type="company" xlink:href="amersham">Amersham</named-content>). Subsequent to application of the  avidin&#x02013;biotin blocking kit (Vector), rabbit&#x02013;anti human CD40 antibody (1:250; Santa Cruz), anti-muscle actin mAb for SMC  (Enzo Diagnostics), anti-CD31 mAb for EC (1:400, Dako), or  anti-CD68 mAb for M&#x000d8; (1:600; Dako) were added and sections incubated overnight at 4&#x000b0;C. Subsequently, the appropriate  secondary antibodies were applied for 30 min followed by  Streptavidin&#x02013;FITC (<named-content content-type="company" xlink:href="amersham">Amersham</named-content>). To detect stromelysin-3 in mouse  atherosclerotic lesions, the stromelysin-3 mAb and a specific anti&#x02013; mouse absorbed rat biotinylated secondary antibody (1:500), followed by avidin&#x02013;biotin&#x02013;peroxidase complex, were applied.</p></sec><sec disp-level="3"><title>Biochemical Analysis of Human Atherosclerotic Lesions.</title><p>Frozen tissue from five nonatherosclerotic arteries and seven atheromatous  carotid plaques were homogenized (IKA-Labortechnik, Ultra-turrax T 25) and lysed (0.3 mg tissue/ml lysis buffer) as described  previously (<xref ref-type="bibr" rid="B5">5</xref>). The lysates were clarified (16,000 <italic>g</italic>, 15 min) and  the protein concentration for each tissue extract as well as for the  cell culture samples was determined using a bicinchoninic acid  protein assay according to the instructions of the manufacturer  (Pierce). 50 &#x003bc;g total protein were applied to Western blot analysis.</p></sec><sec disp-level="3"><title>In Situ Hybridization.</title><p>In situ hybridization was performed according to the instructions of the manufacturer (Hyb-Probe&#x02122;;  Shandon/Lipshaw). Frozen tissue sections, obtained as described  above, were fixed in cold acetone, air-dried, and incubated with  a mixture of FITC labeled stromelysin-3&#x02013;specific (5&#x02032;-GGTACCGTCAACCAGGTCCTCGTCCACG-3&#x02032;; 5&#x02032;-CTCAGAGTCGGGTCTACTGACCGTCC-3&#x02032;; 5&#x02032;-CCTACTGGTCCCGTGTCTGGACGACGTCCA-3&#x02032;; 5&#x02032;-ACGGTCCGGTGCTTATAGTCC-GATCTCCTGG-3&#x02032;), CD40L-specific (5&#x02032;-TTATGGGTGTCAA-GGCGGTTTGGAACGCCCGTT-3&#x02032;; 5&#x02032;-TGAAAAACGACA-CATAGAAGTATCTTCCAA-3&#x02032;; 5&#x02032;-TACTAGCTTTGTATGTTGGTTTGAAGAGGGGCT-3&#x02032;; 5&#x02032;-TGCAGGAAACCGAATGAGTTTGAGACTTGT-3&#x02032;), or random oligomers in hybridization buffer (30% formamide, 0.6 M NaCl<sub>2</sub>, 10% dextran sulfate,  50 mM Tris [pH 7.5], 0.1% sodiumpyrophosphate, 0.2% Ficoll, 5  mM EDTA) for 10 min at 65&#x000b0;C and subsequently for 2 h at 37&#x000b0;C  in a moist chamber. Thereafter, slides were immersed in TBS/ Triton (50 mM Tris, 150 mM NaCl, pH 7.6/0.1% Triton  X-100) to allow coverslips to float off and were washed (TBS/ Triton) three times for 3 min at 37&#x000b0;C. The slides were forwarded  to the immunological reaction by incubation with blocking solution (10 min, rt) and subsequent addition of the alkaline phosphatase&#x02013;conjugated rabbit Fab&#x02032; anti FITC (30 min, rt, moist  chamber) as the primary detection reagent. Finally, the slides  were washed twice in TBS (3 min, rt), covered with alkaline  phosphatase substrate buffer (5 min, rt), and developed using the  NBT/BCIP (nitro-blue-tetrazolium/5-bromo-4-chloro-3-indolyl  phosphate) chromogen solution (1&#x02013;2 h, rt, moist chamber).</p></sec><sec disp-level="3"><title>Western Blotting and Radioimmunoprecipitation.</title><p>Cell extracts  (25 &#x003bc;g total protein/lane) and culture supernatants were separated by standard SDS-PAGE under reducing conditions and  blotted to polyvinylidene difluoride membranes (Bio-Rad) using  a semidry blotting apparatus (0.8 mA/cm<sup>2</sup>, 30 min; Bio-Rad).  Blots were blocked and first and second monoclonal antibodies  were diluted in 5% defatted dry milk/PBS/0.1% Tween 20. After  1 h of incubation with the respective primary antibody, blots  were washed three times (PBS/0.1% Tween 20) and the secondary, peroxidase&#x02013;conjugated, goat anti&#x02013;mouse antibody (Jackson  ImmunoResearch) was added for another hour. Finally, the blots  were washed (20 min, PBS/0.1% Tween 20) and immunoreactive proteins were visualized using the Western blot chemiluminescence system (NEN&#x02122;).</p><p>For radioimmunoprecipitation experiments, cells were washed  and further incubated with unlabeled medium lacking methionine/cysteine. Subsequently, medium containing 10% FBS and  50 mCi/ml [<sup>35</sup>S]methionine/cysteine (NEN&#x02122;) was added to the  cells for 24 h. Supernatants were harvested and concentrated  (10&#x000d7;) using Centricon 3 devices (Amicon). Immunoprecipitation buffer (50 mM Tris-HCl, 0.1% SDS, 0.1% sodium deoxycholate, 1% NP-40, 150 mM NaCl, 5 mM EDTA, 20 &#x003bc;g/ml  soybean trypsin inhibitor, 0.1% mM PMSF, 0.2 U/ml aprotinin,  0.025% sodium azide) was added to the cultures and cells were  harvested by scraping. Subsequently, non immune mouse serum  (Vector) was added (24 h, 4&#x000b0;C) to preclear the samples. Antigens  in supernatants and cell extracts were immunoprecipitated with  the specific anti stromelysin-3 antibody 5ST-4A9 (2 h, 4&#x000b0;C) and  pelleted by subsequent addition of rabbit anti&#x02013;mouse IgG (18 h,  4&#x000b0;C) as well as protein A&#x02013;Sepharose beads (2 h, 4&#x000b0;C). The beads  were washed four times in 50 mM Tris-HCl and finally 50 &#x003bc;l  SDS-PAGE loading buffer (200 mmol/liter Tris, 5% glycerol,  0.1% SDS, 3% &#x003b2;-mercaptoethanol, 0.1 mg/ml bromophenol  blue) was added. After heating the samples 5 min at 95&#x000b0;C, supernatants were separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes. Blots were dried and exposed to  x-ray film for detection of the immunoprecipitated antigen.</p></sec><sec disp-level="3"><title>Isolation of RNA and PCR.</title><p>Total RNA from unstimulated or  stimulated (24 h) EC, SMC, or M&#x000d8; was isolated by a one-step  preparation according to the method of Chomczynski and Sacchi  (<xref ref-type="bibr" rid="B50">50</xref>). The cDNA was prepared by reverse transcription (RT) of  total RNA (1 &#x003bc;g) with oligo(dT) using superscript reverse transcriptase (<named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>). The RT products were diluted in 480 &#x003bc;l  twice distilled water and 10 &#x003bc;l of these cDNA preparations were  mixed on ice with 10 &#x003bc;l primers (20 &#x003bc;M), 80 &#x003bc;l reaction mix  (including 10 ml of PCR buffer, 2.5 mM MgCl), 4 &#x003bc;l dNTPs  (200 &#x003bc;M; final concentration), and 0.5 &#x003bc;l Taq-polymerase (2.5 U;  all <named-content content-type="company" xlink:href="gibco">GIBCO BRL</named-content>). PCR was performed for 35 cycles at 95&#x000b0;C  (120 s), 62&#x000b0;C (120 s), and 72&#x000b0;C (180 s, 2 s prolongation per cycle)  after hot start. The sequences of primers for human stromelysin-3  were 5&#x02032;-CTGCAGTCATCTGGGCTGAGACTC-3&#x02032; and 5&#x02032;-CCATGGCAGTTGGTGCAGGAGCAG-3&#x02032;. The primers were  obtained from Integrated DNA Technologies. Aliquots of the  PCR products were run on 1.3% agarose gels and visualized by  UV transillumination.</p></sec><sec disp-level="3"><title>In Vivo Analysis of CD40L-mediated Stromelysin-3 Expression.</title><p>LDLR<sup>&#x02212;/&#x02212;</sup> at a minimum age of 8 wk were fed a high cholesterol  diet (1.25% cholesterol, 0% cholate; Research Diets) and treated  for a period of 12 wk with either rat IgG (control) or rat anti&#x02013; mouse CD40L (M158) antibody (both at 250 &#x003bc;g per mouse  twice a week intraperitoneal; both provided by <named-content content-type="company" xlink:href="immunex">Immunex Corp.</named-content>)  (<xref ref-type="bibr" rid="B51">51</xref>). Thereafter, the mice (10 per group) were killed, the aortic  arches embedded, and tissue sections examined by immunohistochemistry as described below. The extent of lesion formation  and the expression of vascular adhesion molecule-1 in these animals  has been reported separately (<xref ref-type="bibr" rid="B51">51</xref>). No difference in the serum lipid  profiles (total cholesterol, very low density lipoprotein, low density  lipoprotein, and high density lipoprotein [analyzed by fast protein  liquid chromatography] or triglycerides) or in circulating leukocytes, hematocrit, or body weight was observed among the groups.</p></sec></sec><sec id="Results"><title>Results</title><sec disp-level="4"><title>Expression of Stromelysin-3 in Human Atherosclerotic  Plaques.</title><p>Immunohistochemical analysis of the expression  of stromelysin-3 in normal aortic specimens (<italic>n</italic> &#x0003d; 5; Fig. <xref ref-type="fig" rid="F1">1</xref> A,  left) and human atherosclerotic fatty streaks (<italic>n</italic> &#x0003d; 5; data  not shown) revealed little or no expression of the enzyme.  In contrast, well-developed human carotid atherosclerotic  lesions (<italic>n</italic> &#x0003d; 7) consistently showed strong stromelysin-3  immunoreactivity, most prominently at the luminal border  and in the shoulder region of the plaque (Fig. <xref ref-type="fig" rid="F1">1</xref> A, right).  Western Blot analysis, performed on protein extracts of the  surgical specimens and using the identical antibody used for  the immunohistochemistry studies, revealed barely detectable immunoreactive stromelysin-3 in control specimens  but markedly increased levels of the proteinase in atherosclerotic tissue (Fig. <xref ref-type="fig" rid="F1">1</xref> B). The immunoreactive bands detected had molecular masses of &#x0223c;64, 48, 35, and 28 kD,  corresponding to the zymogen, intermediate, and active  forms of stromelysin-3 (9, 10, 22, 23, 52, and 53). Higher  magnifications of the immunohistochemical analysis, as  well as immunofluorescent double staining with respective  cell-selective antibodies, localized stromelysin-3 within  EC, SMC, and M&#x000d8; of the plaque (Fig. <xref ref-type="fig" rid="F2">2</xref>). Tissues showed  no staining with the respective control IgG1 antibody (data  not shown). Because we recently localized CD40 and  CD40L in human atherosclerotic plaques and have shown  that CD40 ligation induces interstitial collagenases and gelatinases in atheroma-associated cells (<xref ref-type="bibr" rid="B41">41</xref>&#x02013;<xref ref-type="bibr" rid="B43">43</xref>), we investigated the possible colocalization of stromelysin-3 with  CD40. Indeed, cells expressing stromelysin-3 also bear  CD40 (Fig. <xref ref-type="fig" rid="F3">3</xref>). Furthermore, we analyzed the cellular localization of stromelysin-3 transcripts by in situ hybridization (Fig. <xref ref-type="fig" rid="F4">4</xref>). Human atheroma (Fig. <xref ref-type="fig" rid="F4">4</xref>, C&#x02013;E), but not normal arteries (Fig. <xref ref-type="fig" rid="F4">4</xref>, A and B), contained stromelysin-3  mRNA. Within the atherosclerotic lesion, stromelysin-3  transcripts localized most prominently at the luminal border and the shoulder region of the plaques, areas described  above as positive for the immunoreactive protein. The  staining for the transcripts colocalized with smooth muscle  cell- and macrophage-like cells (Fig. <xref ref-type="fig" rid="F4">4</xref>, D and E) as well  as the endothelium (Fig. <xref ref-type="fig" rid="F4">4</xref> E). Furthermore, transcripts for the  immune mediator CD40L showed a similar distribution on  adjacent sections (Fig. <xref ref-type="fig" rid="F4">4</xref>, G and H). In situ hybridization with  negative control probes did not yield any signal (Fig. <xref ref-type="fig" rid="F4">4</xref> F).    </p></sec><sec disp-level="4"><title>Ligation of CD40 on Human Vascular Endothelial and SMC  as well as M&#x000d8; Induces De Novo Expression of Stromelysin-3.</title><p>To determine the mechanisms involved in stromelysin-3  expression in atheroma-associated cells, we analyzed the  expression of the enzyme in human vascular EC and SMC  as well as in human mononuclear phagocytes in vitro. Human vascular EC, SMC, and M&#x000d8; released immunoreactive  stromelysin-3 constitutively in moderate amounts. Stimulation of the cells with the classical mediators of MMP regulation, IL-1 (1 and 10 ng/ml), TNF-&#x003b1; (5 and 50 ng/ml), or  IFN&#x003b3; (100 and 1,000 U/ml), did not affect the expression  of stromelysin-3, as illustrated here for IL-1 and SMC (Fig.  <xref ref-type="fig" rid="F5">5</xref>). However, the immunohistochemical studies presented  above indicated possible involvement of the CD40&#x02013; CD40L signaling pathway. Stimulation with both T cell&#x02013; derived as well as recombinant human CD40L induced  stromelysin-3 expression in all three cell types (Figs. <xref ref-type="fig" rid="F5">5</xref> and  <xref ref-type="fig" rid="F6">6</xref>). Besides an increased intensity of the higher (&#x0223c;64 kD)  molecular mass band, which corresponds to the molecular  mass of the stromelysin-3 zymogen, CD40 ligation induced  the expression of immunoreactive proteins of lower molecular mass, corresponding to the molecular mass of the active cleavage products of the zymogen (Fig. <xref ref-type="fig" rid="F5">5</xref>). In control  experiments, addition of blocking anti-CD40L antibody  during stimulation of the cells with native or recombinant  ligand inhibited induction of stromelysin-3 expression.  </p><p>Among the cell types analyzed, the immunoreactive  forms of stromelysin-3 detected after CD40 ligation  showed slight differences in the intensity of the respective  bands but were identical in molecular mass. In vascular  SMC, CD40 ligation concentration and time dependently  elevated expression of the 64-kD protein, as well as induced immunoreactive proteins with molecular masses of  &#x0223c;48 and &#x0223c;28 kD. The induction of the lower molecular  mass forms of stromelysin-3 in cultures of SMC required  stimulation with 3&#x02013;10 &#x003bc;g/ml rCD40L (Fig. <xref ref-type="fig" rid="F6">6</xref> A). An increase in the 64-kD protein, as well as in the &#x0223c;48-kD immunoreactive protein, occurred after 1 h of stimulation,  whereas detection of the 28-kD band required at least 6&#x02013;12 h  of exposure to CD40L, as determined by Western blot  analysis (data not shown) and radioimmunoprecipitation  experiments (Fig. <xref ref-type="fig" rid="F7">7</xref>). The patterns of immunoreactive proteins detected in cultures of vascular smooth muscle cells  resembled those found in fibroblasts, an established source  of stromelysin-3 (data not shown). The pattern of immunoreactive bands observed with supernatants of CD40L-stimulated EC (Fig. <xref ref-type="fig" rid="F6">6</xref> B) resembled that obtained with cultures of SMC, except that the 64-kD form was much less  abundant in EC. </p><p>Macrophages, derived from monocytes cultured for 9 d,  showed an additional immunoreactive protein at &#x0223c;35 kD.  Stimulation with &#x02265;0.3 &#x003bc;g/ml rCD40L increased levels of  immunoreactive proteins with apparent molecular masses  of 64, 48, 35, and 28 kD (Fig. <xref ref-type="fig" rid="F6">6</xref> C). Induction of these immunoreactive bands required at least 6 h of stimulation  (data not shown). Specificity of the antibody used was confirmed by Western blot analysis performed with the antistromelysin-3 antibody preincubated with recombinant  stromelysin-3 (Fig. <xref ref-type="fig" rid="F6">6</xref>, blocking). In contrast to monocyte-derived M&#x000d8; cultured for 9 d, freshly isolated peripheral  blood monocytes expressed stromelysin-3 neither constitutively nor when stimulated with rCD40L (Fig. <xref ref-type="fig" rid="F6">6</xref> D). Responsiveness of monocyte-derived cells to CD40 ligation  required a minimum of three days of in vitro culture (data  not shown).</p><p>The stromelysin-3 expression induced by CD40 ligation  in human vascular EC, SMC, and M&#x000d8; resulted from de  novo synthesis of the protein. Metabolic labeling and immunoprecipitation experiments yielded autoradiographic  bands resembling the patterns of immunoreactive proteins  observed by Western blot analysis as shown here for vascular SMC (Fig. <xref ref-type="fig" rid="F7">7</xref>). In accordance with our protein analysis,  RT-PCR experiments showed increased product corresponding to stromelysin-3 transcript after CD40 ligation in  EC and SMC as well as M&#x000d8; (data not shown).</p></sec><sec disp-level="4"><title>Interruption of CD40&#x02013;CD40L Signaling Diminished Stromelysin-3 Expression in Mouse Atherosclerotic Lesions.</title><p>The in  situ observations of stromelysin-3 expression in human  atherosclerotic plaques, in combination with the in vitro  findings that CD40 ligation selectively mediates the expression of stromelysin-3, suggested an in vivo evaluation of  the importance of CD40&#x02013;CD40L signaling for the expression of this enzyme within atherosclerotic plaques. For this  purpose, an established animal model of arteriosclerosis was  used: LDLR<sup>&#x02212;/&#x02212;</sup> mice were fed a high cholesterol (1.25%)  diet to develop atherosclerotic lesions (<xref ref-type="bibr" rid="B51">51</xref>). Immunohistochemical analysis of lesions within the aortic arch as well  as the thoracic portion of the aorta revealed a stromelysin-3  expression pattern similar to that found in human atherosclerotic plaques. All three vascular cell types&#x02014;EC, SMC  and M&#x000d8;&#x02014;within the lesions stained for the proteinase.  Treatment of the mice with rat IgG (<italic>n</italic> &#x0003d; 8) did not affect  the stromelysin-3 expression (Fig. <xref ref-type="fig" rid="F8">8</xref> A) compared to controls. In contrast, mice treated with the anti&#x02013;mouse CD40L  antibody (<italic>n</italic> &#x0003d; 8) showed substantially reduced immunoreactivity for stromelysin-3 within the atherosclerotic lesions  (Fig. <xref ref-type="fig" rid="F8">8</xref> B). Since the anti-CD40L antibody treatment also  resulted in a decrease of total plaque number and area (<xref ref-type="bibr" rid="B51">51</xref>),  lesions of similar sizes within the treatment groups were  compared. No immunoreactivity was observed in tissues  stained with the control IgG1 antibody (data not shown). </p></sec></sec><sec id="Discussion"><title>Discussion</title><p>This study establishes the expression of stromelysin-3 in  advanced human atheroma and furthermore provides evidence for (a) colocalization of this matrix metalloproteinase  with CD40 on lesional EC, SMC, and M&#x000d8; in situ and (b)  regulation of de novo expression of stromelysin-3 by  CD40 ligation, rather than by the classical soluble mediators of MMPs such as IL-1, TNF-&#x003b1;, or IFN-&#x003b3;. We also  demonstrated in vivo that the interruption of CD40&#x02013; CD40L interaction markedly reduced the expression of  stromelysin-3 in mouse atheroma. The finding that EC,  SMC, and M&#x000d8; express stromelysin-3 establishes atheroma-associated cells as novel sources of stromelysin-3. Thus, this  report provides evidence that stromelysin-3, whose expression correlates with the invasiveness of malignancies (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B11">11</xref>,  <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B54">54</xref>), might also participate in the pathogenesis of  another common human disease, atherosclerosis. In view of  its unusual substrate specificity, stromelysin-3 might participate in several pathways. The pattern of stromelysin-3 expression within tissues that undergo extensive remodeling  in pathological (carcinomas; 11, 12, 16, 17, 54) as well as  physiological (placenta and uterus; 11, 18) events, indicates  a role for stromelysin-3 in these processes. Although related  by sequence to the MMP family, stromelysin-3 does not  hydrolyze many of the extracellular matrix components  that are substrates for other MMPs such as fibronectin,  laminin, elastin, or collagen type I and type IV (<xref ref-type="bibr" rid="B23">23</xref>). From  this perspective, the enzyme has been considered a nonmatrix&#x02013;degrading metalloproteinase. Instead, stromelysin-3  appears to act as a predominant regulator of serpin function. Interestingly, a recent report postulated that extracellular matrix degradation might depend not only on an  imbalance between matrix metalloproteinases and their  inhibitors, but might accelerate in face of decreased levels  of certain serpins such as &#x003b1;<sub>2</sub>-M, &#x003b1;<sub>2</sub>-AP, or &#x003b1;<sub>1</sub>-PI (<xref ref-type="bibr" rid="B33">33</xref>),  preferred substrates of stromelysin-3 (<xref ref-type="bibr" rid="B23">23</xref>). Pathways by  which this enzyme might regulate matrix degradation include (a) inactivation of matrix-degrading, enzyme-inhibiting serpins as described for cathepsins (<xref ref-type="bibr" rid="B32">32</xref>) or for elastolytic activity by &#x003b1;<sub>1</sub>-PI, shown to simultaneously augment  the proliferative and invasive activity of cells (<xref ref-type="bibr" rid="B23">23</xref>); (b)  activation of other members of the MMP family (<xref ref-type="bibr" rid="B17">17</xref>) copiously expressed in atheroma, such as interstitial collagenase,  gelatinases A and B, and stromelysin-1 (<xref ref-type="bibr" rid="B5">5</xref>) (at sites of  chronic inflammation, such as atherosclerosis, constitutively  active stromelysin-3 [9] might act proximally to promote  conversion of the zymogen forms of these classical MMPs  to their active forms); and (c) degradation of matrix molecules not cleaved by the classical MMPs such as extracellular proteins containing amino acids with unusual long side  chains, including those generated in vivo by certain posttranslational modifications (<xref ref-type="bibr" rid="B55">55</xref>). Thus, matrix degradation,  a critical step in the progression from the stable atheroma  to one prone to rupture and capable of causing thrombotic  complications, might indeed involve the action of stromelysin-3. The serpin-degrading function of stromelysin-3  may thus have significance beyond tumor invasion and  metastasis.</p><p>Furthermore, the action of stromelysin-3 on serpins also  might affect atherosclerosis by pathways other than extracellular matrix remodeling. Serpins regulate multiple functions associated with the disease, including (a) blood pressure (e.g., the serpin &#x003b1;<sub>1</sub>&#x02013;antitrypsin inhibits renin and thus  renin&#x02013;angiotensinogen interaction, as well as angiotensinogen itself [30]), (b) fibrinolysis (e.g., the serpin &#x003b1;<sub>1</sub>&#x02013;antiplasmin targets plasmin, a key effector of fibrinolysis [23]), (c)  blood coagulation (e.g., the serpins anti-thrombin III and  heparin cofactor II rapidly interact with thrombin in the  presence of heparin [31]), or (d) lipoprotein uptake (cleavage of the serpins &#x003b1;<sub>1</sub>-antitrypsin and &#x003b1;<sub>2</sub>-macroglobulin is  associated with increased low density lipoprotein uptake  into cells, indicating that those cleaved serpins disturb the  intracellular cholesterol homeostasis [27&#x02013;29]). Aside from  these effects, stromelysin-3 might further affect atherosclerosis via the insulin-like growth factor&#x02013;insulin-like growth  factor binding protein (IGF&#x02013;IGFBP) system. Human atheroma contain IGF-1 and IGFBPs (<xref ref-type="bibr" rid="B56">56</xref>). These mediators are  associated with cardiovascular pathophysiology particularly  via their critical role in vascular growth (<xref ref-type="bibr" rid="B57">57</xref>). IGF-1 directly  accelerates arteriosclerosis in rat aorta allografts via myointimal proliferation and intimal thickening (<xref ref-type="bibr" rid="B58">58</xref>). The level of  free, biologically active IGF-1 depends on the degree of  complex formation with the respective binding proteins. A  recent study identified IGFBP-1 as a potential physiological  substrate for human stromelysin-3 (<xref ref-type="bibr" rid="B59">59</xref>). Finally, IGF also acts  as a survival factor for human vascular SMC derived from  normal vessels as well as coronary atherosclerotic plaques  (<xref ref-type="bibr" rid="B60">60</xref>), suggesting stromelysin-3 may prevent apoptosis of vascular SMC by augmenting IGF-1 levels.</p><p>The potential relevance of serpin degradation for the  pathogenesis of atherosclerosis in humans is supported by  reports showing that levels of several serpins, including  AT-III (<xref ref-type="bibr" rid="B36">36</xref>), &#x003b1;<sub>2</sub>-M, and &#x003b1;<sub>2</sub>-AP (<xref ref-type="bibr" rid="B35">35</xref>), decrease in this prevalent disease. In addition, recent in vivo studies demonstrated that serpins inhibit coronary restenosis in atherosclerotic swine (<xref ref-type="bibr" rid="B37">37</xref>) and atherosclerotic plaque development in  rabbits post injury (<xref ref-type="bibr" rid="B38">38</xref>). Our findings that (a) differentiated  atherosclerotic lesions but not their precursor, the fatty  streak, bear stromelysin-3; (b) the immunoreactive bands  detected within the atheromatous plaques resembled  mostly the pattern obtained with M&#x000d8; in vitro; and (c) only  differentiated M&#x000d8;, but not peripheral blood monocytes,  exhibit stromelysin-3 induction; support a role of this enzyme in the late rather than the early states of atherosclerosis. Interestingly, the Rotterdam study showed increased  AT-III levels in moderate peripheral arterial atherosclerosis  and decreased levels in more severe atherosclerosis (<xref ref-type="bibr" rid="B61">61</xref>).</p><p>Future studies will have to establish whether these various functions apply to human atherosclerosis and whether  stromelysin-3 is the crucial mediator in reduction of all or  only certain atheroma-associated serpin activities. However, based on the recently burgeoning background information on stromelysin-3, our findings suggest functions of  this proteinase in regulation of plaque progression and  (in)stability by mechanisms distinct from those ascribed to  members of the MMP family, including augmented extracellular matrix degradation, promotion of blood coagulation, decreased fibrinolytic activity, and dysregulation of  blood pressure as well as lipoprotein catabolism. The colocalization of stromelysin-3 with CD40 and CD40L within  the human atherosclerotic lesion, as well as the demonstration that CD40L, rather than the classical mediators of  MMPs, induce stromelysin-3 expression in atheroma-associated cells demonstrate CD40&#x02013;CD40L signaling as a new,  and, as indicated by the in vivo studies, probably crucial  pathway of stromelysin-3 induction.</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Expression of stromelysin-3 in human atherosclerotic  plaques. (A) Frozen sections of normal human arterial tissue and human  atheromatous plaques were stained for stromelysin-3. The tissue was analyzed using horseradish peroxidase&#x02013;mediated immunohistochemistry on  adjacent sections (red reaction product). No immunoreactivity was observed in tissue stained with the respective control IgG1 antibody (data  not shown). The lumen of the artery is at the top of each photomicrograph (&#x000d7;100). Analysis of five normal aortic tissue and seven atheroma  obtained from different donors showed similar results. (B) Extracts (50  &#x003bc;g/ml) of three nonatherosclerotic tissue (Normal) and atheromatous  plaques (Atheromatous) were separated by standard SDS-PAGE under reducing conditions and analyzed by Western blotting for stromelysin-3 expression. The positions of the molecular mass markers are indicated (kD).  Analysis of five normal tissues as well as seven atheromatous lesions from  different donors showed similar results.</p></caption><graphic xlink:href="JEM981883.f1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Colocalization of stromelysin-3  with endothelial cells, smooth muscle cells,  and macrophages in human atheroma. High  power views (&#x000d7;400) of frozen sections of  human carotid lesions showed specific staining for stromelysin-3 (right, red staining) on  human vascular endothelial cells (EC),  smooth muscle cells (SMC), and macrophages (M&#x000d8;) within the plaque. Cell types  were characterized by immunofluorescence  double staining (left, green staining) as described in Materials and Methods. The lumen of the artery is at the top of each photomicrograph. Analysis of seven atheroma  from different donors showed similar results.</p></caption><graphic xlink:href="JEM981883.f2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Colocalization of stromelysin-3 with CD40 in human atherosclerotic lesions. Frozen sections of normal human atheromatous  plaques were stained for stromelysin-3 and CD40 by immunofluorescence double staining (stromelysin-3 in red, CD40 in green). No immunoreactivity was observed in tissue stained with the respective control  IgG1 antibody (data not shown). The lumen of the artery is at the top of  each photomicrograph (&#x000d7;100). Analysis of five normal aortic tissue and  seven atheroma obtained from different donors showed similar results.</p></caption><graphic xlink:href="JEM981883.f3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Human stromelysin-3 mRNA colocalizes with EC, SMC,  and M&#x000d8; of the atherosclerotic lesion. In situ hybridization analysis of  nonatherosclerotic tissue (A and B) revealed no detectable stromelysin-3  mRNA signal, in contrast to atheromatous plaques (C&#x02013;E). Higher magnification (&#x000d7;400) of stromelysin-3 mRNA-positive areas revealed colocalization with M&#x000d8;-like (D), as well as EC- and SMC-like (E) cell types  within the lesion. Negative control probes yielded no detectable signal  (F). Areas of the plaque and cell types similar to those found positive for  stromelysin-3 stained also for CD40L mRNA (G and H). Analysis of  three atheroma from different donors showed similar results.</p></caption><graphic xlink:href="JEM981883.f4"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>CD40L induces stromelysin-3 in human vascular smooth  muscle cells in vitro. Human vascular SMC, cultured 24 h before the experiment in insulin/transferrin medium, were incubated (24 h) with  membranes of 50 ng/ml PMA-stimulated (12 h) CD4<sup>&#x0002b;</sup> T lymphocytes (T  cell membranes, ratio equivalent to 1 SMC:10 T cells), 1 or 10 &#x003bc;g/ml recombinant human CD40 ligand (rCD40L), or 10 ng/ml IL-1&#x003b2; in the absence or presence of an anti-CD40L antibody (1 &#x003bc;g/ml &#x003b1;-CD40L). Concentrated (10&#x000d7;) supernatants were analyzed by Western blotting for  stromelysin-3 protein expression. The positions of the molecular weight  markers are indicated (kD). Data shown are representative of three experiments performed with SMC from different donors.</p></caption><graphic xlink:href="JEM981883.f5"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>CD40L induces stromelysin-3 in atheroma-associated cells in  a concentration dependent fashion. Human vascular smooth muscle cells  (SMC), endothelial cells (EC), monocyte&#x02013;derived macrophages after 9 d  in culture (M&#x000d8;), and freshly isolated peripheral blood monocytes  (PBMC), cultured 24 h before the experiment in the respective serum-free medium, were incubated (24 h) with the respective concentrations of  recombinant human CD40 ligand (rCD40L). Concentrated (10&#x000d7;) supernatants were analyzed by Western blotting for stromelysin-3 protein expression. For specificity control, the primary antibody was blocked (1 h,  37&#x000b0;C) with recombinant stromelysin-3 (10 &#x003bc;g/ml) before applied to parallel samples of supernatants of 3 &#x003bc;g/ml rCD40L&#x02013;stimulated cultures  (blocking, right lanes). The positions of the molecular mass markers are  indicated (kD). Data shown are representative of three to six experiments  performed with cells from different donors.</p></caption><graphic xlink:href="JEM981883.f6"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>CD40 ligation induces de novo stromelysin-3 expression in human vascular  SMC. Human vascular SMC,  cultured 24 h before the experiment in DMEM lacking methionine/cysteine, were incubated for the indicated times  with 10 &#x003bc;g/ml rCD40L in the  presence of 50 &#x003bc;Ci/ml [<sup>35</sup>S]methionine/cysteine. Antigen was  immunoprecipitated from concentrated (10&#x000d7;) culture supernatants with the specific antistromelysin-3 antibody and blots were dried and exposed to x-ray film for  detection. The positions of the molecular mass markers are indicated  (kD). Data shown are representative of three experiments performed with  SMC obtained from different donors.</p></caption><graphic xlink:href="JEM981883.f7"/></fig><fig position="float" id="F8"><label>Figure 8</label><caption><p>Interruption of CD40&#x02013;CD40L signaling in hyperlipidemic  LDLR<sup>&#x02212;/&#x02212;</sup> mice reduces stromelysin-3 expression in atherosclerotic  plaques. High power views of frozen sections of aorta from LDLR<sup>&#x02212;/&#x02212;</sup>  mice fed a high cholesterol diet and treated with rat IgG for control (IgG)  or rat anti&#x02013;murine CD40L antibody (&#x003b1;-CD40L) (both at 250 &#x003bc;g/ml, intraperitonally, twice per week) are shown. Plaques of approximately similar size were chosen for comparison. The lumen of the artery is at the top  of each photomicrograph. Analysis of aortas obtained from eight different  mice of each group showed similar results.</p></caption><graphic xlink:href="JEM981883.f8"/></fig></sec><ack><p>We thank Maria Muszynski, Eugenia Shvartz, and Elissa Simon-Morrissey (Brigham and Women's Hospital) for their skillful technical assistance.</p><p>This work was supported in part by grants from the National Heart, Lung, and Blood Institute to Dr. Peter  Libby (HL-43364) and the Swiss National Research Fund to Dr. Fran&#x000e7;ois Mach and was performed during  the tenure of the Paul Dudley White fellowship of the American Heart Association by Dr. Uwe Sch&#x000f6;nbeck.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manuel</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>C</given-names></name><name><surname>Risau</surname><given-names>W</given-names></name><name><surname>Clauss</surname><given-names>M</given-names></name></person-group><article-title>Tumor necrosis: factors and principles</article-title><source>Immunol Today</source><year>1996</year><volume>17</volume><fpage>254</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">8962625</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moscatelli</surname><given-names>D</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name></person-group><article-title>Membrane and matrix localization of proteinases: A common theme in tumor cell invasion and angiogenesis</article-title><source>Biochim Biophys Acta</source><year>1988</year><volume>948</volume><fpage>67</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">2456098</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Bellocq</surname><given-names>JP</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Stromelysin-3 gene expression in human cancer: an overview</article-title><source>Invasion Metastasis</source><year>1995</year><volume>14</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">7657519</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henney</surname><given-names>AM</given-names></name><name><surname>Wakeley</surname><given-names>PR</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Foster</surname><given-names>K</given-names></name><name><surname>Hembry</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Humphries</surname><given-names>S</given-names></name></person-group><article-title>Localization  of stromelysin gene expression in atherosclerotic plaques by  <italic>in situ</italic>hybridization</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>8154</fpage><lpage>8158</lpage><pub-id pub-id-type="pmid">1896464</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galis</surname><given-names>ZS</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Lark</surname><given-names>MW</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques</article-title><source>J Clin Invest</source><year>1994</year><volume>94</volume><fpage>2493</fpage><lpage>2503</lpage><pub-id pub-id-type="pmid">7989608</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Hibbs</surname><given-names>MS</given-names></name><name><surname>Kearney</surname><given-names>M</given-names></name><name><surname>Loushin</surname><given-names>C</given-names></name><name><surname>Isner</surname><given-names>JM</given-names></name></person-group><article-title>Identification of 92 kD gelatinase in human coronary atherosclerotic lesions</article-title><source>Circulation</source><year>1995</year><volume>91</volume><fpage>2125</fpage><lpage>2131</lpage><pub-id pub-id-type="pmid">7697840</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="other">Lee, R.T., and P. Libby. 1996. Metalloproteinases and atherosclerotic plaque rupture. <italic>In</italic> The Role of Immune Mechanisms. H.-P. Schultheiss and P. Schwimmbeck, editors.  Springer Verlag, New York. 21:238&#x02013;246.</citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>The matrix-degrading metalloproteinases</article-title><source>Bioessays</source><year>1992</year><volume>14</volume><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">1445287</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>SJ</given-names></name></person-group><article-title>Furin-dependent intracellular activation of the human stromelysin-3 zymogen</article-title><source>Nature</source><year>1995</year><volume>375</volume><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">7746327</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santavicca</surname><given-names>M</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Angliker</surname><given-names>H</given-names></name><name><surname>Stoll</surname><given-names>I</given-names></name><name><surname>Segain</surname><given-names>J-P</given-names></name><name><surname>Anglard</surname><given-names>P</given-names></name><name><surname>Chretien</surname><given-names>M</given-names></name><name><surname>Seidah</surname><given-names>N</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases</article-title><source>Biochem J</source><year>1996</year><volume>315</volume><fpage>953</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">8645182</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basset</surname><given-names>P</given-names></name><name><surname>Bellocq</surname><given-names>JP</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Stoll</surname><given-names>I</given-names></name><name><surname>Hutin</surname><given-names>P</given-names></name><name><surname>Limacher</surname><given-names>JM</given-names></name><name><surname>Podhajcer</surname><given-names>OL</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas</article-title><source>Nature</source><year>1990</year><volume>348</volume><fpage>699</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">1701851</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>SN</given-names></name><name><surname>Ruhri</surname><given-names>C</given-names></name><name><surname>Kunth</surname><given-names>K</given-names></name><name><surname>Holecek</surname><given-names>BU</given-names></name><name><surname>Hoefler</surname><given-names>H</given-names></name><name><surname>Atkinson</surname><given-names>MJ</given-names></name></person-group><article-title>Expression of stromelysin-3 in the stromal elements of human basal cell carcinoma</article-title><source>Diag  Mol Pathol</source><year>1992</year><volume>1</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">1342967</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urbanski</surname><given-names>SJ</given-names></name><name><surname>Edwards</surname><given-names>DR</given-names></name><name><surname>Maitland</surname><given-names>A</given-names></name><name><surname>Leco</surname><given-names>KJ</given-names></name><name><surname>Watson</surname><given-names>A</given-names></name><name><surname>Kossakowska</surname><given-names>AE</given-names></name></person-group><article-title>Expression of matrix metalloproteinase and their inhibitors in primary pulmonary carcinomas</article-title><source>Br J Cancer</source><year>1992</year><volume>66</volume><fpage>1188</fpage><lpage>1194</lpage><pub-id pub-id-type="pmid">1457364</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polette</surname><given-names>M</given-names></name><name><surname>Clavel</surname><given-names>C</given-names></name><name><surname>Birembaut</surname><given-names>P</given-names></name><name><surname>De Clerck</surname><given-names>YA</given-names></name></person-group><article-title>Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 in human head and neck carcinomas</article-title><source>Pathol Res Pract</source><year>1993</year><volume>189</volume><fpage>1052</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">8302724</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>H&#x000e4;hnel</surname><given-names>E</given-names></name><name><surname>Harvey</surname><given-names>JM</given-names></name><name><surname>Joyce</surname><given-names>R</given-names></name><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Sterrett</surname><given-names>GF</given-names></name><name><surname>H&#x000e4;hnel</surname><given-names>R</given-names></name></person-group><article-title>Stromelysin-3 expression in breast cancer biopsies: clinico-pathological correlation</article-title><source>Int J Cancer</source><year>1993</year><volume>55</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8344741</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Durand De Grossouvre</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>JP</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing</article-title><source>J Investig Dermatol</source><year>1992</year><volume>99</volume><fpage>870</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">1469302</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nawrocki</surname><given-names>B</given-names></name><name><surname>Polette</surname><given-names>M</given-names></name><name><surname>Clavel</surname><given-names>C</given-names></name><name><surname>Morrone</surname><given-names>A</given-names></name><name><surname>Eschard</surname><given-names>JP</given-names></name><name><surname>Etienne</surname><given-names>JC</given-names></name><name><surname>Birembaut</surname><given-names>P</given-names></name></person-group><article-title>Expression of stromelysin 3 and tissue inhibitors of matrix metalloproteinases, Timp-1 and Timp-2, in rheumatoid arthritis</article-title><source>Pathol  Res Pract</source><year>1994</year><volume>190</volume><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">7808967</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>O</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Limacher</surname><given-names>JM</given-names></name><name><surname>Hutin</surname><given-names>P</given-names></name><name><surname>Wendling</surname><given-names>C</given-names></name><name><surname>LeMeur</surname><given-names>M</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name></person-group><article-title>The breast cancer&#x02013;associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis</article-title><source>J Cell Biol</source><year>1992</year><volume>119</volume><fpage>997</fpage><lpage>1002</lpage><pub-id pub-id-type="pmid">1429845</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>WH</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name><name><surname>Giudice</surname><given-names>LC</given-names></name><name><surname>Dsupin</surname><given-names>B</given-names></name><name><surname>Cannon</surname><given-names>P</given-names></name><name><surname>Svitek</surname><given-names>C</given-names></name><name><surname>Gorstein</surname><given-names>F</given-names></name><name><surname>Osteen</surname><given-names>KG</given-names></name></person-group><article-title>Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones</article-title><source>J Clin Invest</source><year>1994</year><volume>94</volume><fpage>946</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">8083380</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>O</given-names></name><name><surname>Regnier</surname><given-names>C</given-names></name><name><surname>Chenard</surname><given-names>MP</given-names></name><name><surname>Wendling</surname><given-names>C</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name></person-group><article-title>Developmental expression of mouse stromelysin-3 mRNA</article-title><source>Development</source><year>1995</year><volume>121</volume><fpage>947</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">7743938</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>No&#x000eb;l</surname><given-names>A</given-names></name><name><surname>Santavicca</surname><given-names>M</given-names></name><name><surname>Stoll</surname><given-names>I</given-names></name><name><surname>L'Hoir</surname><given-names>C</given-names></name><name><surname>Staub</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>22866</fpage><lpage>22872</lpage><pub-id pub-id-type="pmid">7559421</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Segain</surname><given-names>J-P</given-names></name><name><surname>O'Shea</surname><given-names>M</given-names></name><name><surname>Cockett</surname><given-names>M</given-names></name><name><surname>Ioannou</surname><given-names>C</given-names></name><name><surname>Lefebvre</surname><given-names>O</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>15435</fpage><lpage>15441</lpage><pub-id pub-id-type="pmid">8340372</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>D</given-names></name><name><surname>Majmudar</surname><given-names>G</given-names></name><name><surname>Weiss</surname><given-names>SJ</given-names></name></person-group><article-title>Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>25849</fpage><lpage>25855</lpage><pub-id pub-id-type="pmid">7523394</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Potempa</surname><given-names>J</given-names></name><name><surname>Korzus</surname><given-names>E</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group><article-title>The serpin superfamily of proteinase inhibitors: structure, function, and regulation</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>15957</fpage><lpage>15960</lpage><pub-id pub-id-type="pmid">8206889</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>K</given-names></name><name><surname>Bieth</surname><given-names>J</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group><article-title>Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin</article-title><source>J Biol  Chem</source><year>1990</year><volume>255</volume><fpage>3931</fpage><lpage>3934</lpage><pub-id pub-id-type="pmid">6989830</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duranton</surname><given-names>J</given-names></name><name><surname>Adam</surname><given-names>C</given-names></name><name><surname>Bieth</surname><given-names>JG</given-names></name></person-group><article-title>Kinetic mechanism of the inhibition of cathepsin G by alpha1-antichymotrypsin and alpha1-proteinase inhibitor</article-title><source>Biochemistry</source><year>1998</year><volume>37</volume><fpage>11239</fpage><lpage>11245</lpage><pub-id pub-id-type="pmid">9698370</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janciauskiene</surname><given-names>S</given-names></name><name><surname>Al</surname><given-names>O</given-names></name><name><surname>Rayyes</surname></name><name><surname>Floren</surname><given-names>C-H</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name></person-group><article-title>Low density lipoprotein catabolism is enhanced by the cleaved form of alpha-1-antitrypsin</article-title><source>Scand J Clin Lab  Investig</source><year>1997</year><volume>57</volume><fpage>325</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">9249880</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasza</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>HH</given-names></name><name><surname>Heegaard</surname><given-names>CW</given-names></name><name><surname>Oka</surname><given-names>K</given-names></name><name><surname>Christensen</surname><given-names>A</given-names></name><name><surname>Dubin</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Andreasen</surname><given-names>PA</given-names></name></person-group><article-title>Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low density-lipoprotein-receptor-related protein</article-title><source>Eur J Biochem</source><year>1997</year><volume>248</volume><fpage>270</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">9346278</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janciauskiene</surname><given-names>S</given-names></name><name><surname>Lindgren</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>HT</given-names></name></person-group><article-title>The C-terminal peptide of alpha-1-antitrypsin increases low density lipoprotein binding in HepG2 cells</article-title><source>Eur J Biochem</source><year>1998</year><volume>254</volume><fpage>460</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">9688255</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scharpe</surname><given-names>S</given-names></name><name><surname>Eid</surname><given-names>M</given-names></name><name><surname>Cooreman</surname><given-names>W</given-names></name><name><surname>Lauwers</surname><given-names>A</given-names></name></person-group><article-title>Alpha-1-Anti-trypsin, an inhibitor of renin</article-title><source>Biochem J</source><year>1976</year><volume>153</volume><fpage>505</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">1084151</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pratt</surname><given-names>CW</given-names></name><name><surname>Church</surname><given-names>FC</given-names></name></person-group><article-title>General features of the heparin-binding serpins antithrombin, heparin cofactor II, and protein C inhibitor</article-title><source>Blood</source><year>1993</year><volume>4</volume><fpage>479</fpage><lpage>490</lpage></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schick</surname><given-names>C</given-names></name><name><surname>Kamachi</surname><given-names>Y</given-names></name><name><surname>Bartuski</surname><given-names>AJ</given-names></name><name><surname>Cataltepe</surname><given-names>S</given-names></name><name><surname>Schechter</surname><given-names>NM</given-names></name><name><surname>Pemberton</surname><given-names>PA</given-names></name><name><surname>Silverman</surname><given-names>GA</given-names></name></person-group><article-title>Squamous cell carcinoma-antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>1849</fpage><lpage>1855</lpage><pub-id pub-id-type="pmid">8999871</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oleksyszyn</surname><given-names>J</given-names></name><name><surname>Augustine</surname><given-names>AJ</given-names></name></person-group><article-title>Plasminogen modulation of IL1-stimulated degradation in bovine and human articular cartilage explants. The role of the endogenous inhibitors, PAI-1, alpha-2-antiplasmin, alpha-1-PI, alpha-2-macroglobulin and TIMP</article-title><source>Inflamm Res</source><year>1996</year><volume>45</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">8891758</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornebeck</surname><given-names>W</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name></person-group><article-title>Elastase-like enzymes in aortas and human breast carcinomas: quantitative variations with age and pathology</article-title><source>Adv Exp Med Biol</source><year>1977</year><volume>79</volume><fpage>145</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">68661</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohacsi</surname><given-names>A</given-names></name><name><surname>Fulop</surname><given-names>T</given-names></name><name><surname>Kozlovszky</surname><given-names>B</given-names></name><name><surname>Hauck</surname><given-names>M</given-names></name><name><surname>Kiss</surname><given-names>I</given-names></name><name><surname>Leovey</surname><given-names>A</given-names></name></person-group><article-title>Sera and leukocyte elastase-type protease and antiprotease activity in healthy and atherosclerotic subjects of various ages</article-title><source>J Gerontol</source><year>1992</year><volume>47</volume><fpage>154</fpage><lpage>158</lpage></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>JR</given-names></name><name><surname>Etherington</surname><given-names>MD</given-names></name><name><surname>Jamieson</surname><given-names>S</given-names></name><name><surname>Lawford</surname><given-names>P</given-names></name><name><surname>Lincoln</surname><given-names>SV</given-names></name><name><surname>Alkjaersig</surname><given-names>NJ</given-names></name></person-group><article-title>Blood changes in atherosclerosis and long after myocardial infarction and venous thrombosis</article-title><source>Thromb Diath Haemorrh</source><year>1975</year><volume>34</volume><fpage>483</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">53892</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>MN</given-names></name><name><surname>Mazur</surname><given-names>W</given-names></name><name><surname>Kleinman</surname><given-names>NS</given-names></name><name><surname>Rodgers</surname><given-names>GP</given-names></name><name><surname>Abukhalil</surname><given-names>JM</given-names></name><name><surname>French</surname><given-names>BA</given-names></name><name><surname>Raizner</surname><given-names>AE</given-names></name></person-group><article-title>Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine</article-title><source>Coron Artery Dis</source><year>1996</year><volume>7</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">8993944</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Macen</surname><given-names>J</given-names></name><name><surname>Nash</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>E</given-names></name><name><surname>Stewart</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Etches</surname><given-names>W</given-names></name><name><surname>Boshkov</surname><given-names>L</given-names></name><name><surname>Nation</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty</article-title><source>Circulation</source><year>1996</year><volume>94</volume><fpage>2890</fpage><lpage>2900</lpage><pub-id pub-id-type="pmid">8941118</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>A</given-names></name><name><surname>Bellocq</surname><given-names>J-P</given-names></name><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Chenard</surname><given-names>M-P</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas</article-title><source>Proc Natl Acad Sci USA</source><year>1995</year><volume>92</volume><fpage>2730</fpage><lpage>2734</lpage><pub-id pub-id-type="pmid">7708715</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anglard</surname><given-names>P</given-names></name><name><surname>Melot</surname><given-names>T</given-names></name><name><surname>Guerin</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Structure and promotor characterization of the human stromelysin-3 gene</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>20337</fpage><lpage>20344</lpage><pub-id pub-id-type="pmid">7657606</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Bourcier</surname><given-names>T</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis</article-title><source>Proc Natl  Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>1931</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">9050882</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Murphy</surname><given-names>C</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name><name><surname>Fabumni</surname><given-names>RP</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Regulation of  matrix-metalloproteinase expression in human vascular  smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? </article-title><source>Circ Res</source><year>1997</year><volume>81</volume><fpage>448</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">9285647</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Activation of monocyte/macrophage function related to acute atheromata complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>396</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">9244201</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazzei</surname><given-names>GJ</given-names></name><name><surname>Edgerton</surname><given-names>MD</given-names></name><name><surname>Losberger</surname><given-names>C</given-names></name><name><surname>Lecoanet-Henchoz</surname><given-names>S</given-names></name><name><surname>Graber</surname><given-names>P</given-names></name><name><surname>Durandy</surname><given-names>A</given-names></name><name><surname>Gauchat</surname><given-names>J-F</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Allet</surname><given-names>B</given-names></name><name><surname>Bonnefoy</surname><given-names>J-Y</given-names></name></person-group><article-title>Recombinant soluble trimeric CD40 ligand is biologically active</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>7025</fpage><lpage>7028</lpage><pub-id pub-id-type="pmid">7706236</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santavicca</surname><given-names>M</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Chenhard</surname><given-names>M-P</given-names></name><name><surname>Lutz</surname><given-names>Y</given-names></name><name><surname>Stoll</surname><given-names>I</given-names></name><name><surname>Segain</surname><given-names>J-P</given-names></name><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Rio</surname><given-names>MC</given-names></name><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Belloco</surname><given-names>J-P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Characterization of monoclonal antibodies against stromelysin-3 and their use to evaluate stromelysin-3 levels in breast carcinoma by semi-quantitative immunohistochemistry</article-title><source>Int J Cancer</source><year>1995</year><volume>64</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">7591307</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MK</given-names></name><name><surname>Picha</surname><given-names>KS</given-names></name><name><surname>Fanslow</surname><given-names>WC</given-names></name><name><surname>Grabstein</surname><given-names>KH</given-names></name><name><surname>Alderson</surname><given-names>MR</given-names></name><name><surname>Clifford</surname><given-names>KN</given-names></name><name><surname>Chin</surname><given-names>WA</given-names></name><name><surname>Mohler</surname><given-names>KM</given-names></name></person-group><article-title>CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages</article-title><source>Eur J Immunol</source><year>1996</year><volume>26</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">8617306</pub-id></citation></ref><ref id="B47"><label>47</label><citation citation-type="other">Ross, R., and B. Kariya. 1980. Morphogenesis of vascular  smooth muscle in atherosclerosis and cell structure. <italic>In</italic> Handbook of Physiology, The Cardiovascular System. D.F. Bohr,  A.P. Somlyo, and H.Y. Sparks, editors. American Physiological Society, Bethesda, MD. 66&#x02013;91.</citation></ref><ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>O'Brien</surname><given-names>KV</given-names></name></person-group><article-title>Culture of quiescent arterial smooth muscle cells in a defined serum-free medium</article-title><source>J  Cell Physiol</source><year>1983</year><volume>115</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">6302107</pub-id></citation></ref><ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>B&#x000f6;yum</surname><given-names>A</given-names></name></person-group><article-title>Isolation of mononuclear cells and granulocytes from human blood</article-title><source>Scand J Clin Lab Investig</source><year>1968</year><volume>21</volume><fpage>77</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">5637478</pub-id></citation></ref><ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chomczynski</surname><given-names>P</given-names></name><name><surname>Sacchi</surname><given-names>N</given-names></name></person-group><article-title>Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction</article-title><source>Anal Biochem</source><year>1987</year><volume>162</volume><fpage>156</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">2440339</pub-id></citation></ref><ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Sch&#x000f6;nbeck</surname><given-names>U</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Atkinson</surname><given-names>E</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Reduction of atherosclerosis in a mouse model by interruption of CD40-CD40L signaling</article-title><source>Nature</source><year>1998</year><volume>394</volume><fpage>200</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">9671306</pub-id></citation></ref><ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerin</surname><given-names>E</given-names></name><name><surname>Ludwig</surname><given-names>M-G</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name><name><surname>Anglard</surname><given-names>P</given-names></name></person-group><article-title>Stromelysin-3 induction and interstitial collagenase repression by retinoic acid</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>11088</fpage><lpage>11095</lpage><pub-id pub-id-type="pmid">9111003</pub-id></citation></ref><ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mari</surname><given-names>BP</given-names></name><name><surname>Anderson</surname><given-names>IC</given-names></name><name><surname>Mari</surname><given-names>SE</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Lutz</surname><given-names>Y</given-names></name><name><surname>Kobzik</surname><given-names>L</given-names></name><name><surname>Shipp</surname><given-names>MA</given-names></name></person-group><article-title>Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism</article-title><source>J  Biol Chem</source><year>1998</year><volume>273</volume><fpage>618</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">9417124</pub-id></citation></ref><ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>C</given-names></name><name><surname>Rouyer</surname><given-names>N</given-names></name><name><surname>Lutz</surname><given-names>Y</given-names></name><name><surname>Adida</surname><given-names>C</given-names></name><name><surname>Loriot</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>JP</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name></person-group><article-title>Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>1843</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">8446598</pub-id></citation></ref><ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mucha</surname><given-names>A</given-names></name><name><surname>Cuniasse</surname><given-names>P</given-names></name><name><surname>Kannan</surname><given-names>R</given-names></name><name><surname>Beau</surname><given-names>F</given-names></name><name><surname>Yiotakis</surname><given-names>A</given-names></name><name><surname>Basset</surname><given-names>P</given-names></name><name><surname>Dive</surname><given-names>V</given-names></name></person-group><article-title>Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently substrates containing unusual amino acids in their P1&#x02032; positions</article-title><source>J Biol  Chem</source><year>1998</year><volume>273</volume><fpage>2763</fpage><lpage>2768</lpage><pub-id pub-id-type="pmid">9446583</pub-id></citation></ref><ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>MB</given-names></name><name><surname>Wargovich</surname><given-names>TJ</given-names></name><name><surname>Ellis</surname><given-names>EA</given-names></name><name><surname>Tarnuzzer</surname><given-names>R</given-names></name><name><surname>Caballero</surname><given-names>S</given-names></name><name><surname>Estes</surname><given-names>K</given-names></name><name><surname>Rossing</surname><given-names>M</given-names></name><name><surname>Spoerri</surname><given-names>PE</given-names></name><name><surname>Pepine</surname><given-names>C</given-names></name></person-group><article-title>Expression of IGF-I, IGF-I receptor and IGF binding proteins-1, -2, -3, -4, and -5 in human atheroectomy specimens</article-title><source>Regul Pept</source><year>1996</year><volume>67</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">8988513</pub-id></citation></ref><ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delafontaine</surname><given-names>P</given-names></name></person-group><article-title>Insulin-like growth factor I and its binding proteins in the cardiovascular system</article-title><source>Cardiovasc Res</source><year>1995</year><volume>30</volume><fpage>825</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">8746194</pub-id></citation></ref><ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>N</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Maurice</surname><given-names>P</given-names></name><name><surname>Foegh</surname><given-names>ML</given-names></name></person-group><article-title>Acceleration of arteriosclerosis of the rat aorta allograft by insulin growth factor-I</article-title><source>Transplantation</source><year>1997</year><volume>63</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">9112342</pub-id></citation></ref><ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manes</surname><given-names>S</given-names></name><name><surname>Mira</surname><given-names>E</given-names></name><name><surname>Barbacid</surname><given-names>MM</given-names></name><name><surname>Cipres</surname><given-names>A</given-names></name><name><surname>Fernandez-Resa</surname><given-names>P</given-names></name><name><surname>Buesa</surname><given-names>JM</given-names></name><name><surname>Merida</surname><given-names>I</given-names></name><name><surname>Aracil</surname><given-names>M</given-names></name><name><surname>Marquez</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>AC</given-names></name></person-group><article-title>Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>25706</fpage><lpage>25712</lpage><pub-id pub-id-type="pmid">9325295</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Schwartz</surname><given-names>SM</given-names></name></person-group><article-title>Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaque</article-title><source>J Clin  Invest</source><year>1995</year><volume>95</volume><fpage>2266</fpage><lpage>2274</lpage><pub-id pub-id-type="pmid">7738191</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Bom</surname><given-names>JG</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>van Vliet</surname><given-names>HH</given-names></name><name><surname>Pols</surname><given-names>HA</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name></person-group><article-title>Antithrombin and atherosclerosis in the Rotterdam Study</article-title><source>Arterioscler Thromb  Vasc Biol</source><year>1996</year><volume>16</volume><fpage>864</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">8673561</pub-id></citation></ref></ref-list><fn-group><fn id="FN1"><label>1</label><p><italic>Abbreviations used in this paper:</italic> &#x003b1;<sub>2</sub>-AP, &#x003b1;<sub>2</sub>-antiplasmin; &#x003b1;<sub>1</sub>-AT, &#x003b1;<sub>1</sub>-antitrypsin; &#x003b1;<sub>2</sub>-M, &#x003b1;<sub>2</sub>-macroglobulin; &#x003b1;<sub>1</sub>-PI, &#x003b1;<sub>1</sub>-proteinase inhibitor; AT-III,  antithrombin III; EC, endothelial cells; FBS, fetal bovine serum; IGF,  insulin-like growth factor; IGFBP, insulin-like growth factor binding  protein; LDLR<sup>&#x02212;/&#x02212;</sup>, low density lipoprotein receptor deficient; MMP,  matrix metalloproteinase; M&#x000d8;, macrophages; PMA, Phorbol-12 myristate  13-acetate; RT, reverse transcription; SMC, smooth muscle cells.</p></fn></fn-group></back></article>


